Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 129,303

Document Document Title
WO/2018/047848A1
To provide a nerve regeneration-inducing tube having improved properties and a material thereof. A compound having a structure in which (A) to (C) are bonded together and (B) and (C) are adjacent to each other: (A) an oligomer comprising...  
WO/2018/047178A1
The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of...  
WO/2018/041739A1
The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic...  
WO/2018/042018A3
The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that adm...  
WO/2018/044895A1
The disclosure is directed to immediate release dosage forms comprising an active agent portion comprising an active pharmaceutical agent and about 30% to about 99%, based on the weight of the dosage form, of an alcohol resistant agent. ...  
WO/2018/044896A1
Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the tr...  
WO/2018/041942A1
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...  
WO/2018/042018A2
The present invention relates to an approach for the treatment of adverse neurological sensations in a certain body surface area such as the skin, in particular treatment of pain or itching. The invention is based on the finding that adm...  
WO/2018/042423A1
The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long ...  
WO/2018/042384A1
Compositions comprising extracts prepared from mixtures of the herbal plants Radix Bupleurum chinense DC ("B"), Rhizoma Corydalis yanhusuo WT Wang ("Y"), Caulis Polygonum multiflorum Thunb ("P") and Flos Albizia julibrissin Durazz ("A") ...  
WO/2018/045250A1
Provided herein are methods of treating a disease, such as Parkinson's disease, that is due to increased poly [ADP-ribose] polymerase 1 (PARP-1) activation, by inhibiting macrophage migration inhibitory factor (MIF) nuclease activity.  
WO/2018/042182A1
The present invention relates to compositions for use in the treatment, prevention or management of neurological degeneration or dementia, comprising inhibitors or antagonists of monomeric C-reactive protein (mCRP), and optionally, the i...  
WO/2018/041812A1
The present invention relates to the field of neurodegenerative diseases, and the prevention and/or treatment of TBC1D24-associated disorders, such as DOORS syndrome, (intractable) epilepsy, and nonsyndromic deafness. In particular, the ...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/042362A1
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/042096A1
The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indol-1-yl-(1H)quinolin-2-one and indol-3-yl-(1H)quin...  
WO/2018/045178A1
Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.  
WO/2018/043674A1
Provided are: a composition for activating neurogenesis; use of the same; and a method for preventing, improving, inhibiting the progress and/or treating disorders and the like of the central and/or peripheral nervous systems. The presen...  
WO/2018/040627A1
Use of catalpol in preparation of a drug for preventing and treating or delaying the onset of myasthenia and/or amyotrophy, including myasthenia and/or amyotrophy caused by diabetes, and myasthenia and/or amyotrophy caused by defect of d...  
WO/2018/043714A1
The purpose of the present invention is to efficiently produce microglia from a pluripotent stem cells. Provided is a method for producing microglia from pluripotent stem cells, comprising the following steps: (a) a step of co-culturing ...  
WO/2018/045276A8
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/042362A9
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/041269A1
Disclosed are a transdermal administration formulation system for delivering a specific nanobody biomedicine through skin tissue and a preparation method and the use thereof. By optimizing the formulation of the carrier, and maintaining ...  
WO/2018/045083A1
Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual ...  
WO/2018/045276A1
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/045045A1
Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substi...  
WO/2018/041919A1
The present invention relates to a compound of the following formula (A): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a disease associated with a mitochondrial dysfunction.  
WO/2018/039378A1
This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disub...  
WO/2018/035616A1
Provided are novel peptides of Formula SEQ ID No. 1: J1CysX1X2X3X4X5X6ProX7ThrCysJ2J3(J4)s(J5)t; (SEQ ID No. 1) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are which are effective inhibitors ...  
WO/2018/039147A1
Described are methods of inhibiting neurodegeneration in a subject by administering to the subject an agent that prevents (alpha)-syn PFF from binding to its receptor. The agent may be a small molecule chemical compound, antibody, nuclei...  
WO/2018/036080A1
The invention provides an application of an amino adamantane mononitrate in preparing a drug for preventing and treating diseases such as glaucoma, vascular dementia, subarachnoid hemorrhage, pulmonary arterial hypertension, and the like...  
WO/2018/039642A1
Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof...  
WO/2018/038022A1
Provided is a means whereby the skin permeability of rivastigmine can be improved without adversely affecting the adhesiveness of a patch. A non-aqueous patch comprising a support, a drug-containing adhesive layer and a release liner, wh...  
WO/2018/035751A1
A Cordyceps sinensis health supplement containing traditional Chinese medicine extracts and a preparation method therefor. The health supplement comprises the following raw materials in parts by weight: 20-40 parts of Folium Mori extract...  
WO/2018/039062A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful as a BACE1 inhibitor.  
WO/2018/038599A1
The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or...  
WO/2018/038265A1
The present invention provides: a novel use of a specific bicyclic nitrogenated heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogenated heterocyclic compound having a PDE7 inhibition activity, a method for producing the ...  
WO/2018/039190A1
A kit for treating psychosis by administering a pharmaceutically acceptable liquid composition of Asenapine to oral mucosa includes a formulation having Asenapine, or a pharmaceutically acceptable salt or hydrate thereof, ethanol, and wa...  
WO/2018/038255A1
The purpose of the present invention is to provide crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia, the crystals being useful as pharmaceuticals. The present invention provides crysta...  
WO/2018/039526A1
Methods for managing pain, treating pain, and treating neurodegenerative disorders. The methods include administering to a subject in need thereof: (A) a therapeutically effective amount of simvastatin or a pharmaceutically acceptable sa...  
WO/2018/039159A1
A combination of a M2-receptor antagonist and a non-anticholinergic antiemetic agent, and optionally an anticholinesterase inhibitor, to treat hypocholinergic disorders such as Alzheimer type dementia, schizophrenia, schizophrenia associ...  
WO/2018/037306A1
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfen...  
WO/2018/038973A1
Peptide analogues of β-amyloid and methods of using said analogues for neuroprotection are described herein. The β-amyloid peptide analogues have a sequence that is at least 50% identical to an N-terminal β-amyloid core fragment. A ph...  
WO/2018/039545A3
Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 dom...  
WO/2018/039545A2
Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 dom...  
WO/2018/033149A1
Provided are crystal forms of Ozanimod and a preparation method therefor. The provided crystal forms of Ozanimod comprise a crystal form CS9, a crystal form CS10, and a crystal form CS11 of Ozanimod, and can be used for treating autoimmu...  
WO/2018/034345A1
The present invention pertains to a composition for improving peripheral neuropathy caused by the administration of anticancer agents, the composition comprising a milk protein hydrolysate and protein derived from fermented milk as prote...  
WO/2018/034330A1
The purpose of the present invention is to provide a novel composition for promoting ketone body formation. The present invention provides a composition for promoting ketone body formation, the composition containing one or more amino ac...  
WO/2018/032611A1
A neuroprotective agent, comprising a compound as represented by formula (I).  
WO/2018/035477A1
The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to...  

Matches 301 - 350 out of 129,303